Yiping Zhang

发表

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Y. Pommier, J. Doroshow, Shar-yin N. Huang, 2012, Cancer research.

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Y. Pommier, Joel Morris, J. Doroshow, 2013, Molecular Cancer Therapeutics.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Jun Ma, Yi-long Wu, Q. Xiu, 2011, The Lancet. Oncology.

Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay.

Yvonne A. Evrard, J. C. Schmitz, R. Parchment, 2016, Seminars in oncology.

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells

L. Rubinstein, J. Doroshow, R. Parchment, 2011, PloS one.

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

D. Visscher, A. Chen, E. Swisher, 2022, Cancer Chemotherapy and Pharmacology.

Therapeutics , Targets , and Chemical Biology Trapping of PARP 1 and PARP 2 by Clinical PARP Inhibitors

Y. Pommier, J. Doroshow, Shar-yin N. Huang, 2012 .

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

E. Sausville, L. Rubinstein, A. Chen, 2016, Clinical Cancer Research.

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of titration with controlled-release oxycodone versus immediate-release morphine in patients with moderate cancer pain

Yiping Zhang, Z. Song, Zhiyong Shi, 2018 .

Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.

Y. Shao, Yiping Zhang, Z. Song, 2018, Lung cancer.

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.

Cheng-ling Zhao, H. Pan, Jiangtao Sun, 2022, Lung cancer.

Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1

Xiaoming Yu, Yiping Zhang, Jian Lin, 2016, Experimental and therapeutic medicine.

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

Yiping Zhang, Z. Song, Wenxian Wang, 2022, BMC Pulmonary Medicine.

Prognostic Value of SPOCD1 in Esophageal Squamous Cell Carcinoma: A Comprehensive Study Based on Bioinformatics and Validation

Yuanji Xu, Yiping Zhang, Lin Chen, 2022, Frontiers in Genetics.

培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的随机、对照、多中心临床研究

Baolan Li, Li Zhang, Jian-hua Chang, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

X. Chen, N. Xu, Yunpeng Liu, 2021, Nature communications.

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

Yiping Zhang, Z. Song, Wenxian Wang, 2022, BMC cancer.

肺癌骨转移诊疗专家共识（2014版）

Mengzhong Liu, Qinghua Zhou, Jun Liang, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway

Xinran Liu, Yiping Zhang, Fenfang Hong, 2021, Biomolecules.

NADPH oxidase 5 (NOX5)—induced reactive oxygen signaling modulates normoxic HIF‐1α and p27Kip1 expression in malignant melanoma and other human tumors

Han Liu, J. Doroshow, H. Makhlouf, 2017, Molecular carcinogenesis.

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Yi-long Wu, Q. Xiu, Chengping Hu, 2012 .

Ultrasensitive gene fusion detection reveals fusion variant associated tumor heterogeneity

Hoi Yee Chu, Zongli Zheng, W. Cho, 2020 .

Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.

Yiping Zhang, Z. Song, Xin-min Yu, 2013, Journal of thoracic disease.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Ying Cheng, Keunchil Park, Yi-long Wu, 2020, The Lancet. Respiratory medicine.

The prognosis analysis of EGFR-TKI targeted treatment combined with chemotherapy in smokers with non-small cell lung cancer

Yiping Zhang, Z. Song, G. Hong, 2017 .

Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.

Yiping Zhang, Z. Song, Xin-min Yu, 2016, Lung cancer.

Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient.

Yiping Zhang, Z. Song, 2014, Journal of thoracic disease.

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib

Yiping Zhang, Z. Song, 2013, Molecular and clinical oncology.

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.

Jianxing He, Y. Shu, Yiping Zhang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究

W. Mao, Yiping Zhang, B. Lin, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析

Yiping Zhang, Z. Song, B. Lin, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

中国肺癌脑转移诊治专家共识（2017年版）

Yang Zhang, B. Han, Jinming Yu, 2017, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Effects of IRAK-4 gene silencing by siRNA on the mitogen-activated protein kinase signaling pathway in osteoblast-like cells

Jincheng Wang, Yiping Zhang, Bo Xu, 2016 .

The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia

Yiping Zhang, Z. Song, Wenxian Wang, 2022, Contrast media & molecular imaging.

The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

Yiping Zhang, Z. Song, Wenxian Wang, 2021, Cancer Immunology, Immunotherapy.

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Ying Cheng, Dong Wang, Yuankai Shi, 2020 .

Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

Bing-he Xu, Z. Shao, Shiying Yu, 2010, Cancer Chemotherapy and Pharmacology.

Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

Yvonne A. Evrard, Y. Pommier, J. Doroshow, 2012, PloS one.

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Qinghua Zhou, Yiping Zhang, Z. Guan, 2005, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa

Yujie Zhang, Yiping Zhang, Huijun Wang, 2016, Cancer biology & therapy.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

Y. Pommier, L. Rubinstein, J. Doroshow, 2016, Cancer Chemotherapy and Pharmacology.

[Advances of treatment of small cell lung cancer in 2011 American Society of Clinical Oncology Annual Meeting].

Yiping Zhang, Shenglin Ma, Hongyang Lu, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

Y. Ba, Jianming Xu, He-long Zhang, 2020, The Lancet. Oncology.

Estrogen Receptor Beta Inhibits The Proliferation, Migration, And Angiogenesis Of Gastric Cancer Cells Through Inhibiting Nuclear Factor-Kappa B Signaling

Yiping Zhang, Lili Wang, Yahua Wu, 2019, OncoTargets and therapy.

Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.

Ying Cheng, R. Guo, Yiping Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial

Yiping Zhang, Z. Song, Shiqing Chen, 2022, BMC Medicine.

lncRNA ZFAS1 Improves Neuronal Injury and Inhibits Inflammation, Oxidative Stress, and Apoptosis by Sponging miR-582 and Upregulating NOS3 Expression in Cerebral Ischemia/Reperfusion Injury

Yiping Zhang, Yanyan Zhang, Yiping Zhang, 2020, Inflammation.

Docetaxel‐based chemotherapy as second‐line regimen for advanced thymic carcinoma

Yiping Zhang, Z. Song, Xin-min Yu, 2014, Thoracic cancer.

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Xuefei Shi, Chuanhao Tang, Guansong Wang, 2022, Thoracic cancer.

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

J. Liu, Jiancheng Luo, Rui Zhang, 2022, Thoracic cancer.

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis

Yiping Zhang, Z. Song, Wenxian Wang, 2018, Archives of medical science : AMS.

Association of Next Generation Sequencing and Routine Testing with Survival of Advanced Non-Small Cell Lung Cancer Patients in Clinical Practice

Yiping Zhang, Z. Song, Wenxian Wang, 2021 .

Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain

Shixiu Wu, H. Pan, Yiping Zhang, 2007, Clinical drug investigation.

Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

Yiping Zhang, Z. Song, 2014, Medical Oncology.

Ef ﬁ cacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Ying Cheng, R. Guo, Yiping Zhang, 2022 .

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Tao Zhang, Wei Shi, Jian-hua Chang, 2022, Cancer communications.

Treatment and prognosis of WHO type A thymoma based on Masaoka-Koga stage

Yiping Zhang, Z. Song, Wenxian Wang, 2019 .

Primary neuroendocrine tumors of the thymus: Clinical review of 22 cases

Yiping Zhang, Z. Song, 2014, Oncology letters.

Treatment Pattern and Overall Survival of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicentric Real-World Study in China (CTONG1506)

Yi-long Wu, P. Yu, D. Zhong, 2020 .

Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP

L. Rubinstein, J. Doroshow, A. Chen, 2009 .

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

Ying Cheng, Y. Ba, Dong Wang, 2021, JAMA.

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Ying Cheng, B. Han, Baolan Li, 2018, British Journal of Cancer.

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

W. Wei, K. Nan, Jun Liang, 2016, Chinese clinical oncology.

Pretreatment neutrophil‐to‐lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinoma

Yiping Zhang, Ying Jin, Chunxiao He, 2015, Head & neck.

Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis

X. Yi, Y. Guan, Ling Yang, 2021, Cell death & disease.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Yvonne A. Evrard, W. Linehan, J. Doroshow, 2016, Clinical Cancer Research.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

S. Steinberg, Y. Pommier, S. Bates, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Ying Cheng, R. Guo, Sheng Hu, 2022, Molecular cancer.

ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.

Zhihua Liu, Hongyan Chen, F. Ding, 2018, Cancer letters.

Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

Zhijian Sun, Yiping Zhang, Z. Song, 2021, Clinical Cancer Research.

TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma.

Zhihua Liu, Yiping Zhang, D. Su, 2020, Cell reports.

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

Xue Wu, Y. Shao, Yiping Zhang, 2016, Oncotarget.

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma

Yiping Zhang, Z. Song, Xin-min Yu, 2016, Cancer medicine.

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

Ming Chen, Yiping Zhang, Z. Song, 2020, Frontiers in Oncology.

PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer

Yiping Zhang, Z. Song, G. Cheng, 2020, Journal of thoracic disease.

Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy

Yiping Zhang, Z. Song, B. Lin, 2014, Chinese medical journal.

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

Ying Cheng, C. Bai, Yi-long Wu, 2013, The Lancet. Oncology.

Rare frequency of gene variation and survival analysis in thymic epithelial tumors

Yiping Zhang, Z. Song, Xin-min Yu, 2016, OncoTargets and therapy.

Salvage treatment with apatinib for advanced non-small-cell lung cancer

Yiping Zhang, Z. Song, G. Lou, 2017, OncoTargets and therapy.

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer

F. Gao, Wei Zhou, Jiancheng Luo, 2022, Thoracic cancer.

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Larry Rubinstein, James H Doroshow, L. Rubinstein, 2012, Clinical Cancer Research.

284 Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Y. Pommier, J. Doroshow, S. Takeda, 2012 .

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay

W. Reinhold, Y. Pommier, J. Doroshow, 2017, PloS one.

Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

James H. Doroshow, Yves Pommier, Shunichi Takeda, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Y. Pommier, L. Rubinstein, L. Jia, 2011, Cancer research.

肺鳞癌驱动基因研究进展

Yiping Zhang, W. Hong, Weizongshu Hong, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

De Novo MET Amplification in Chinese Patients With Non–Small‐Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study

Gang Chen, Yiping Zhang, Z. Song, 2019, Clinical lung cancer.

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

Ying Cheng, T. Mok, Yi-long Wu, 2021, Lung cancer.

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

Baolan Li, Wei Li, Chengping Hu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Yiping Zhang, S. Cai, C. Xie, 2022, BMC Medicine.

Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.

Yiping Zhang, Z. Song, Wenxian Wang, 2019, Lung cancer.

Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients

Wei Wu, Yiping Zhang, Z. Song, 2013, Medical Oncology.

EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.

Yiping Zhang, Shenglin Ma, Ya-ping Xu, 2011, Lung cancer.

Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study

H. Pan, Likun Chen, Yiping Zhang, 2020, Journal of thoracic disease.

Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients

Yiping Zhang, Z. Song, Xin-min Yu, 2017, Cancer biology & therapy.

ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.

Yiping Zhang, Yong Song, Z. Song, 2017, Journal of thoracic disease.

China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

D. Lin, B. Han, Changli Wang, 2017, Asia-Pacific journal of clinical oncology.

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance

Yiping Zhang, Z. Song, Wenxian Wang, 2016, Cancer medicine.

Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.

Yiping Zhang, Z. Song, Xin-min Yu, 2016, Lung cancer.

中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）

B. Han, Jianxing He, Y. Ling, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma

Yiping Zhang, Z. Song, G. Cheng, 2016, Journal of Translational Medicine.

埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析

Xiaowen Jiang, Yiping Zhang, Wenxian Wang, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

B. Han, C. Bai, Jianxing He, 2015, Journal of Thoracic Disease.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

B. Han, C. Bai, Jianxing He, 2015, Journal of thoracic disease.

中国埃克替尼治疗非小细胞肺癌专家共识(2015版)

B. Han, Jianxing He, Y. Ling, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer

Yiping Zhang, Z. Song, 2013, Archives of medical science : AMS.

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).

B. Han, Yiping Zhang, Shucai Zhang, 2014, Lung cancer.

Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases

Yiping Zhang, Z. Song, 2014, Journal of Clinical Neuroscience.

Clinically Useful and Cost-Effective of Recombinant Human Thrombopoietin in Treatment of Chemotherapy Induced Thrombocytopenia

Yiping Zhang, Z. Song, Wenxian Wang, 2020 .

Primary tracheobronchial mucoepidermoid carcinoma - a retrospective study of 32 patients

Yiping Zhang, Yiping Zhang, Z. Song, 2013, World Journal of Surgical Oncology.

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China.

He-long Zhang, Wei Li, Dong Wang, 2020, Chinese clinical oncology.

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

C. Bai, B. Han, Qiang Li, 2018, Investigational New Drugs.

Overexpression of ERβ inhibits the proliferation through regulating TNG-β signaling pathway in osteosarcoma.

Yiping Zhang, Changchang Yin, Lili Wang, 2019, Pathology, research and practice.

Silencing of estrogen receptor β promotes the invasion and migration of osteosarcoma cells through activating Wnt signaling pathway

Yiping Zhang, Changchang Yin, Lili Wang, 2019, OncoTargets and therapy.

Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.

Yi-long Wu, Jian-hua Chang, Chengping Hu, 2021, Lung cancer.

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).

Ying Cheng, T. Mok, Yi-long Wu, 2020, Lung cancer.

Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer

Yiping Zhang, Wenxian Wang, G. Lou, 2018, Medicine.

A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

G. Giaccone, J. Doroshow, R. Parchment, 2010 .

Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.

L. Rubinstein, J. Doroshow, A. Chen, 2010 .

Cancer Biology and Signal Transduction Stereospeci fi c PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Y. Pommier, Joel Morris, J. Doroshow, 2014 .

Ying Cheng, Baolan Li, Yunpeng Liu, 2019, Translational lung cancer research.

Hyponatremia in small cell lung cancer is associated with a poorer prognosis

Yiping Zhang, Z. Song, Wenxian Wang, 2016 .

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Ying Cheng, T. Mok, Yi-long Wu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma translocation: A case report

Yiping Zhang, Z. Song, Wenxian Wang, 2015, Thoracic cancer.

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer

Zhihua Liu, Hongyan Chen, Furong Huang, 2018, OncoTargets and therapy.

Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer

Yiping Zhang, Z. Song, Wenxian Wang, 2021, Cancer management and research.

Brain metastases from esophageal cancer: clinical review of 26 cases.

Yiping Zhang, Z. Song, B. Lin, 2014, World neurosurgery.

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

Ying Cheng, C. Bai, B. Han, 2013, Supportive Care in Cancer.

Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.

Y. Pommier, Ruili Huang, A. Jadhav, 2014, DNA repair.

Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial

Qianchuan Zhao, Bo Zhang, Yiping Zhang, 2022, Pain and Therapy.

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Ying Cheng, Jin-Ji Yang, Jianxing He, 2019, The Lancet. Respiratory medicine.

Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

Y. Pommier, Joel Morris, J. Doroshow, 2014 .

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2019, The Lancet. Respiratory medicine.

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma

Yiping Zhang, J. Ji, A. Mendoza, 2020, Oncogenesis.

MET Gene Amplification and Overexpression in Chinese Non–Small‐Cell Lung Cancer Patients Without EGFR Mutations

Yiping Zhang, Z. Song, Haiyan Su, 2017, Clinical lung cancer.

Cutaneous metastasis as a initial presentation in advanced non-small cell lung cancer and its poor survival prognosis

Yiping Zhang, Z. Song, B. Lin, 2012, Journal of Cancer Research and Clinical Oncology.

Adjuvant therapy in stage II thymic carcinoma

Yiping Zhang, Z. Song, 2014, Journal of Cancer Research and Clinical Oncology.

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Jing Zhu, Ying Cheng, Yi-long Wu, 2022, Targeted Oncology.

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma

Damien Y. Duveau, Michael V. Gormally, Mindy I. Davis, 2017, Clinical Cancer Research.

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

Yi-long Wu, P. Yu, Yiping Zhang, 2017, BMC Cancer.

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

Fei Liu, Jian Feng, N. Yang, 2023, BMC Medicine.

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Study

R. Guo, Yiping Zhang, Wei Zhang, 2022 .

Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma

Yiping Zhang, Z. Song, 2014, OncoTargets and therapy.

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Ying Cheng, Jianming Xu, Yunpeng Liu, 2019, Cancer communications.

X. Chen, Wei Li, Y. Shu, 2022, Nature Communications.

First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.

Ying Cheng, L. Shen, S. Qin, 2021 .

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis

Yiping Zhang, Weiwei Pan, Wenxian Wang, 2023, Open medicine.

Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy

Yiping Zhang, Z. Song, Haiyan Su, 2016, Cancer medicine.

Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

F. Gao, Dong Wang, L. Ye, 2023, Thoracic cancer.

联合血清肿瘤标志物建立预测厄洛替尼治疗复治非小细胞肺癌生存模型

Yiping Zhang, Z. Song, F. Xie, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

H. Pan, Yanqiu Zhao, P. Xing, 2021, Cancer communications.

Anchoring Filament Protein Ladinin-1 is an Immunosuppressive Microenvironment and Cold Tumor Correlated Prognosticator in Lung Adenocarcinoma

Yi Yu, Yuanji Xu, Yiping Zhang, 2023, Biochemical Genetics.

Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open‐label, single‐arm, multicenter trial

Ying Cheng, Jianji Pan, Xiao-dong Zhu, 2015, Head & neck.

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

D. Reinke, K. Ballman, D. Hawkins, 2020, Cancer.

[Analysis of the efficacy and survival of third-line treatment in advanced non-small cell lung cancer].

Yiping Zhang, Z. Song, F. Xie, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.

Ying Cheng, Dong Wang, Yuankai Shi, 2021, The Lancet. Respiratory medicine.

Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201

J. Doroshow, M. Kadota, R. Parchment, 2011 .

Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).

Yi-long Wu, P. Yu, Yiping Zhang, 2018, Lung cancer.

Overexpression Of ERβ Participates In The Progression Of Liver Cancer Via Inhibiting The Notch Signaling Pathway

Yiping Zhang, Lili Wang, Yahua Wu, 2019, OncoTargets and therapy.

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor

Xiaowen Jiang, Yiping Zhang, Z. Song, 2016, OncoTargets and therapy.

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

Yiping Zhang, Xiaoyu Zhu, T. Jiang, 2023, Experimental Hematology & Oncology.

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

He-long Zhang, Yunpeng Liu, Yanqiu Zhao, 2022, Signal Transduction and Targeted Therapy.

Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

Yiping Zhang, Xi Chen, Wei Wang, 2021, BMC Urology.

A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.

Yiping Zhang, Cheng Huang, Xiaoqing Liu, 2012 .

HER2 mutations in Chinese patients with non-small cell lung cancer

Yiping Zhang, Jun Zhao, Z. Song, 2016, Oncotarget.

Treatment and prognosis of type B2 thymoma

Yiping Zhang, Z. Song, Xiangyu Jin, 2014, World Journal of Surgical Oncology.

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma

Yiping Zhang, Z. Song, B. Lin, 2013, Journal of the Chinese Medical Association : JCMA.

JCES01.14 Mutational Profiling of Non-Small-Cell Lung Cancer Patients Resistant to First-Generation EGFR Tyrosine Kinase Inhibitors Using next Generation Sequencing

Yiping Zhang, G. Lou, Ying Jin, 2017 .

Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.

Jianxing He, Y. Shu, Yiping Zhang, 2019, Journal of Clinical Oncology.

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).

R. Xu, Yiping Zhang, Q. Fan, 2021, Journal of Clinical Oncology.

Effective treatment with icotinib in primary adenoid cystic carcinoma of the lung with liver metastasis.

Yiping Zhang, Z. Song, Wei Wu, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer

Daoyuan Wang, Yiping Zhang, Shenglin Ma, 2008, Anti-cancer drugs.

lncRNA ZFAS1 Improves Neuronal Injury and Inhibits Inflammation, Oxidative Stress, and Apoptosis by Sponging miR-582 and Upregulating NOS3 Expression in Cerebral Ischemia/Reperfusion Injury

Yiping Zhang, Yanyan Zhang, 2020, Inflammation.

肺癌分子分型与靶向治疗研究进展

Dan Su, Yiping Zhang, D. Su, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Analysis of the tumor length and other prognosis factors in pT1-2 node-negative esophageal squamous cell carcinoma in a Chinese population

Yiping Zhang, Z. Song, Ji-wen Wang, 2012, World Journal of Surgical Oncology.

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

K. Goto, Jialei Wang, D. Zhong, 2022, Cancer Research.

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Xueqin Chen, H Zhao, Changli Wang, 2023, Nature Cancer.

The deubiquitinase USP11 promotes ovarian cancer chemoresistance by stabilizing BIP

Zhihua Liu, Hongyan Chen, Furong Huang, 2021, Signal Transduction and Targeted Therapy.

Renal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review

Yiping Zhang, Yan Sun, Xinmin Yu, 2014, World Journal of Surgical Oncology.

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.

Ying Cheng, Jin-Ji Yang, C. Bai, 2020, Lung cancer.

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer

Y. Shao, Yiping Zhang, Z. Song, 2020, Translational oncology.

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Jie Yang, Ying Cheng, T. Hsia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer.

Jian-hua Chang, M. Riggi, Y. Shu, 2019, Journal of thoracic disease.

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

L. Ye, Guifang Wang, Yi Hao, 2023, Thoracic cancer.

The efficacy and safety of anlotinib treatment for advanced lung cancer

Yiping Zhang, Z. Song, Wenxian Wang, 2019, OncoTargets and therapy.

Influence of age as a continuous variable on survival outcomes and treatment options in patients with upper thoracic esophageal carcinoma

Yuanji Xu, Yiping Zhang, Junqiang Chen, 2023, Journal of Cancer.

Identification of clinical prognostic features of esophageal cancer based on m6A regulators

Yuanji Xu, Yiping Zhang, Lin Chen, 2022, Frontiers in Immunology.

Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.

Yiping Zhang, Shucai Zhang, K. Ying, 2013 .

The Prognostic Significance of Nomogram-Based Pretreatment Inflammatory Indicators in Patients With Esophageal Squamous Cell Carcinoma Receiving Intensity-Modulated Radiotherapy

Yuanji Xu, Yiping Zhang, Junqiang Chen, 2023, Cancer Control: Journal of the Moffitt Cancer Cente.

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

W. Wei, K. Nan, Jun Liang, 2015, Annals of translational medicine.

Chemotherapy and prognosis in advanced thymic carcinoma patients

Yiping Zhang, Z. Song, Xinmin Yu, 2015, Clinics.

rare frequency of gene variation and survival analysis in thymic epithelial tumors

Yiping Zhang, Z. Song, Xinmin Yu, 2016 .

rare frequency of gene variation and survival analysis in thymic epithelial tumors

Yiping Zhang, Z. Song, Xinmin Yu, 2016 .

中国晚期原发性肺癌诊治专家共识（2016年版）

D. Lin, B. Han, Changli Wang, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Poorer prognosis in patients with advanced gastric squamous cell carcinoma compared with adenocarcinoma of the stomach

Yiping Zhang, Chengsuo Huang, Fang Gao, 2017, Medicine.

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Ying Cheng, Jianbo He, Y. Ba, 2023, Journal of Hematology & Oncology.

Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre.

Yiping Zhang, Z. Song, Z. Song, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study

R. Liu, Y. Ba, T. Deng, 2023, Therapeutic advances in medical oncology.

Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.

Hong Wang, Chao Zhang, Hong Wang, 2023, Thoracic Cancer.

Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis.

Yiping Zhang, X. Gu, 2021, Annals of palliative medicine.

Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.

Yiping Zhang, Z. Song, Xinmin Yu, 2016, Lung cancer.

patients harboring eGFr mutation after primary resistance to crizotinib and response to eGFr-tyrosine kinase inhibitor

Yiping Zhang, Z. Song, Wenxian Wang, 2016 .

Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study

Yiping Zhang, Z. Song, Wenxian Wang, 2018, Medical science monitor : international medical journal of experimental and clinical research.

The ef ﬁ cacy and safety of anlotinib treatment for advanced lung cancer

Yiping Zhang, Z. Song, Wenxian Wang, 2022 .

Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.

Qingshan Li, Ying Cheng, R. Guo, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with Non-Small Cell Lung Cancer: Phase I Study Results.

Yanqiu Zhao, N. Yang, Yiping Zhang, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.